Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

New Study Finds Association Between Small Noncoding RNAs and Cancer

By BiotechDaily International staff writers
Posted on 06 Mar 2014
A team of Canadian molecular biologists has established a link between some types of small noncoding RNAs (smRNAs) and certain cancers.

SmRNAs—RNA molecules that do not give rise to proteins but which may have other important functions in the cell—have been shown to be significantly enriched near the transcriptional start sites of genes. However, the functional relevance of these smRNAs has remained unclear, and they have not been associated with human disease.

Now, in a groundbreaking study, investigators associated with The Cancer Genome Atlas Project (Bethesda, MD, USA) have found that differences in the levels of specific types of noncoding RNAs can be used to distinguish between cancerous and noncancerous tissues. The Cancer Genome Atlas Project is a comprehensive and coordinated effort to accelerate the understanding of the molecular basis of cancer through the application of genome analysis technologies, including large-scale genome sequencing.

In prior cancer studies, these RNAs had been regarded as transcriptional "noise,” due to their apparent chaotic distribution. In contrast, in a study published in the February 1, 2014, issue of the journal EMBO reports investigators at the University of British Columbia (Vancouver, Canada) demonstrated the striking potential of certain smRNAs to distinguish efficiently between cancer and normal tissues and classify patients with cancer to subgroups of distinct survival outcomes.

They stressed that this potential to predict cancer status was restricted to a subset of smRNAs, which was encoded within the first exon of genes, highly enriched within CpG islands and negatively correlated with DNA methylation levels. In a CpG island, both cytosine and the guanine are found on the same strand of DNA or RNA and are connected by a phosphodiester bond.

"For many years, small non-coding RNAs near transcriptional start sites have been regarded as "transcriptional noise" due to their apparent chaotic distribution and an inability to correlate these molecules with known functions or disease," said senior author Dr. Steven Jones, professor of molecular biology at the University of British Columbia. "By using a computational approach to analyze small RNA sequence information that we generated as part of The Cancer Genome Atlas Project, we have been able to filter through this noise to find clinically useful information."

"The data from our experiments show that genome-wide changes in the expression levels of small noncoding RNAs in the first exons of protein-coding genes are associated with breast cancer," said Dr. Jones. "This is the first time that small noncoding RNAs near the transcription start site of genes have been associated with disease. Further work is required but based on our data we believe there is considerable diagnostic potential for these small noncoding RNAs as a predictive tool for cancer. In addition, they may help us understand better the mechanisms underlying oncogenesis at the epigenetic level and lead to potential new drugs employing small noncoding RNAs."

Related Links:

The Cancer Genome Atlas Project
University of British Columbia



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The nano-cocoon drug delivery system is biocompatible, specifically targets cancer cells, can carry a large drug load, and releases the drugs very quickly once inside the cancer cell. Ligands on the surface of the \"cocoon\" trick cancer cells into consuming it. Enzymes (the “worms\" in this image) inside the cocoon are unleashed once inside the cell, destroying the cocoon and releasing anticancer drugs into the cell (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Novel Anticancer Drug Delivery System Utilizes DNA-Based Nanocapsules

A novel DNA-based drug delivery system minimizes damage to normal tissues by utilizing the acidic microenvironment inside cancer cells to trigger the directed release of the anticancer drug doxorubicin (DOX).... Read more

Lab Technologies

view channel

Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.